survodutide vs retatrutide

survodutide (A-tier) vs retatrutide (S-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

survodutide — tier A

boehringer and zealand's glucagon/GLP-1 dual agonist. 16.6% weight loss in the SYNCHRONIZE-1 phase 3, and a standout liver result. investigational, not approved.

a GLP-1 plus glucagon dual agonist with phase 3 obesity data and a breakthrough-tier liver story. still investigational, not FDA-approved.

16.6% SYNCHRONIZE-1 phase 3 · half-life ~6 days · weight loss

retatrutide — tier S

the most potent weight loss drug ever tested. 24.2% in phase 2, then 28.3% in TRIUMPH-1 phase 3, 30.3% at two years. not approved yet.

the triple agonist with the highest weight-loss number ever recorded in a phase 3 obesity trial. not FDA-approved yet.

28.3% TRIUMPH-1 phase 3 · half-life ~6 days · weight loss

at a glance

• survodutide: tier A · 16.6% SYNCHRONIZE-1 phase 3
• retatrutide: tier S · 28.3% TRIUMPH-1 phase 3

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.